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Abstract 
Background: Previous studies have suggested PITX2, KCNN3 and ZFHX3 as atrial fibrillation (AF) susceptibility genes. 
Single common genetic polymorphisms of those genes have been linked with AF phenotypes and rhythm outcome 
of AF catheter ablation although their mechanisms remain elusive. New gene-based association tests may help clari-
fying genotype–phenotype correlations. Therefore, we hypothesized that PITX2, KCNN3 and ZFHX3 associate with left 
atrial enlargement and persistent AF and subsequently with ablation outcome.
Methods and results: Samples from 660 patients with paroxysmal (n = 370) or persistent AF (n = 290) undergoing 
AF catheter ablation were genotyped for ~1,000,000 SNPs. Gene-based association was investigated using two differ-
ent gene-based association tests (VEGAS, minSNP). Among the three candidate genes, only ZFHX3 associated with left 
atrial dilatation and AF recurrence after catheter ablation.
Conclusion: This study suggests a contribution of ZFHX3 to AF remodeling and response to therapy. Future and 
larger studies are necessary to replicate and apply these findings with an emphasis on designing AF pathophysiology-
based multi-locus risk scores.
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Background
Single nucleotide polymorphisms (SNPs) at chromo-
somes 4q25 (PITX2) [1, 2], 16q22 (ZFHX3) [3], and 1q21 
(KCNN3) [4] have been shown to associate with atrial 
fibrillation (AF) in different genome-wide association 
studies (GWAS).
Catheter ablation is an established AF treatment, but 
arrhythmia recurrence occurs in up to 50% of patients 
within 1  year after ablation [5]. Previous work has con-
sistently identified left atrial enlargement and persistent 
AF as clinical predictors for ablation success [6]. Recent 
candidate-gene studies have linked common genetic vari-
ants with intermediate AF phenotypes such as left atrial 
fibrosis [7] as well as rhythm outcome after AF ablation 
[8–10].
However, implicated genetic variants extend over 
broad genomic distances, often spanning several thou-
sands of bases raising the possibility that those loci may 
contain multiple independent susceptibility signals. In 
addition, linkage disequilibrium (LD) structure and geno-
typing coverage may impact on GWAS results when only 
analyzing single SNPs. Consequently, gene-based asso-
ciation tests have been introduced that are well-suited 
to identify genes that may increase susceptibility to com-
plex diseases, phenotypes and response to therapy. They 
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significant, but where no single SNP effect is large 
enough to be genome-wide significant by univariate tests.
Here, for the first time, we apply gene-based analysis 
of GWAS data to test the hypothesis that AF candidate 
genes PITX2, KCNN3 and ZFHX3 associate with left 
atrial enlargement and persistent AF and subsequently 




Six hundred-and-sixty patients with non-valvular AF 
undergoing de-novo radiofrequency AF catheter abla-
tion between 2008 and 2013 were enrolled in the Leipzig 
Heart Center AF ablation registry. Paroxysmal AF was 
defined as self-terminating episodes of AF within 7 days 
after onset documented by ECG or an ambulatory ECG 
monitor. Persistent AF was defined as an AF episode 
either lasting longer than 7  days or requiring drug or 
direct current cardioversion for termination.
Transthoracic and transesophageal echocardiography 
(TEE) was performed prior to catheter ablation. Left 
atrial diameter (LAD) and left ventricular ejection frac-
tion were determined using standard measurements 
and a left atrial thrombus was excluded. All class I or III 
antiarrhythmic medications with the exception of ami-
odarone were discontinued at least 5 half-lives before the 
procedure.
AF catheter ablation and follow‑up
Left atrial catheter ablation was performed using a previ-
ously described approach [8, 11]. In brief, patients were 
studied under deep propofol sedation with continuous 
invasive monitoring of arterial blood pressure and oxy-
gen saturation. Non-fluoroscopic 3D catheter orienta-
tion, CT image integration, and tagging of the ablation 
sites were performed using Ensite NavX, Ensite Velocity 
(St. Jude Medical, St. Paul, MN, USA) or CARTO 3 (Bio-
sense Webster, Diamond Bar, CA, USA). Trans-septal 
access and catheter navigation were performed with a 
steerable sheath (Agilis, St. Jude Medical, St. Paul, MN, 
USA). Patients presenting with AF at the beginning of 
the procedure were electrically cardioverted and ablation 
was performed during sinus rhythm (i.e. AF termination 
by ablation was not attempted). In all patients circum-
ferential left atrial ablation lines were placed around the 
antrum of the ipsilateral pulmonary veins (irrigated tip 
catheter, pre-selected tip temperature of 48 °C, and maxi-
mum power of 20–40 W). In patients with persistent AF, 
linear lesions were added at the left atrial roof, the basal 
posterior wall and the left atrial isthmus or in low volt-
age areas (LVA) until 2011. In patients recruited between 
2011 and 2013, electro-anatomical voltage mapping to 
characterize LVA defined as potentials below 0.5 mV was 
performed as previously described [11]. After circumfer-
ential line placement, voltage and pace mapping along 
the ablation line were used to identify and close gaps. The 
isolation of all pulmonary veins with bidirectional block 
was verified with a multipolar circular mapping catheter 
and was defined as the procedural endpoint. Burst pacing 
from coronary sinus (down to 200 ms) was performed at 
the end of the procedure. If sustained AF was induced, 
patients were electrically cardioverted and no addi-
tional ablation was performed. If atrial tachycardia was 
induced, those were mapped and ablated.
After ablation, class I and III antiarrhythmic drugs 
were not reinitiated. Oral anticoagulation was prescribed 
for 6  months, and proton pump inhibitors were added 
for 4 weeks. All patients were followed in the outpatient 
clinic for 12  months after the ablation. During this fol-
low-up period, 7-day Holter ECG recordings were per-
formed 3, 6 and 12 months after the ablation. Additional 
ECGs and Holter ECG recordings were obtained when 
patients’ symptoms were suggestive of AF. AF recur-
rence was defined as a documented AF episode lasting 
longer than 30 s between 3 and 12 months after the abla-
tion (thus, including a 3-month “blanking period”). All 
patients with sustained early recurring AF underwent 
direct cardioversion. Additional drug administration was 
left to the discretion of the treating physician.
Sample processing
Blood samples were obtained in EDTA test tubes in fast-
ing state prior ablation. Genomic DNA was isolated using 
a commercial kit according to the manufacturer’s recom-
mendations (PeqLab, Erlangen, Germany). Genotyping 
was performed using HumanOmniExpressExome-8-v1.2 
arrays comprising about one million single nucleotide 
polymorphisms (SNPs) according to established proto-
cols (Illumina, San Diego, US).
Data analysis and statistics
Raw data was compiled using GenomeStudio (Illumina) 
software and exported to PLINK GWAs analysis package 
[12]. Using PLINK tool set the data was tested for consist-
ency. Samples with a call rate <95% were excluded. Single 
SNPs had to meet the following criteria: minor allele fre-
quencies (MAF) > 0.01, call rate >95%, Hardy–Weinberg 
equilibrium (HWE) significance threshold >0.0001. Oth-
erwise they were excluded from further analysis.
Association of genotypes with LAD was detected using 
linear regression with adjustment for age, gender, body 
mass index and AF type. Association of genotypes with 
AF type (persistent AF) and arrhythmia recurrence was 
detected using logistic regression analysis with adjust-
ment for age and gender.
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Illumina’s exome arrays contain specific “exm-SNPs” 
which were assigned to their corresponding dbSNP rs 
IDs prior further analysis.
We used two different gene-based tests (minSNP, VEGAS 
[versatile gene-based association study]) whose perfor-
mance depend on different genetic architectures (multiple 
independent signals versus single signal in a gene, size of 
gene, patterns of LD in the gene and so on) [13]. minSNP 
calculates a gene-based P-value either directly from a para-
metric distribution or by using the permuted P-value of 
the best individual SNP association within the given gene. 
minSNP computes single-SNP F-statistics for each SNP 
within a gene and uses the best F-statistic within that gene 
as its test statistic, which is then converted to a P-value 
with gene-based permutations to correct for gene size [13]. 
VEGAS uses the sum of X2 for an individual SNP to gen-
erate a test statistic suggested for the gene. The P-value of 
the gene is then computed after accounting for LD and the 
number of SNPs in each gene [14].
SNPs within 200  kB of the candidate genes were 
selected for inclusion. This range was chosen based 
on previous studies implicating common 4q25 vari-
ants 195 kB upstream of PITX2 in AF susceptibility and 
response to therapy.
We applied a two-stage analysis plan. First, we iden-
tified consistently associated genes with LAD and AF 
type. For this step, a Bonferroni correction was applied 
to account for the analysis of three genes and two pheno-
types (P-value less than 0.05/6 = 0.0083).
Second, association of those identified gene(s) with AF 
ablation outcome was tested. For this analysis, we divided 
the cohort into two data sets based on the ablation period 
and strategy (data set 1: n  =  496, 2008–2011, pulmo-
nary vein isolation ±  linear lesions; data set 2: n = 164, 
2011–2013, pulmonary vein isolation  ±  voltage-guided 
substrate modification) and performed a meta-analysis 
on individual data for the entire cohort.
eQTL analyses of significant SNP(s) were performed 
using the publicly available genotype-tissue expression 
portal (GTEx) of the Broad Institute of Harvard and MIT 
(GTex, Broad Institute, Boston, MA, USA; http://www.
gtexportal.org/home/).
Clinical variables are presented as mean ± one stand-
ard deviation or percentages. They were compared 
between patients with and without AF recurrence using 
Chi square or Student’s t-test.
Results
Patient characteristics
The study population included 660 patients with a his-
tory of paroxysmal (n = 370) or persistent AF (n = 290, 
Table 1). LAD was available in 538 of those data sets and 
could not be analyzed due to insufficient echo conditions 
or performance of TEE only in the remaining patients. 
LAD was significantly larger in patients with persistent 
AF (41  ±  5 vs. 45  ±  6  mm, P  <  1.0E−3) compared to 
patients with paroxysmal AF. Both data sets were differ-
ent with respect to gender, AF type, LAD and LVEF but 
AF recurrence rate was identical (Table 1).
AF recurrence between 3 and 12 months was observed 
in 48% (Table 2) and was associated with LAD (OR 1.05 
per mm increase, 95% CI 1.02–1.08, P  =  1.0E−3) and 
persistent AF (OR 2.1; 95% CI 1.567–2.931, P = 2.0E−6) 
in multivariate analysis.
Genotyping call rate in all subjects was >95% except in 
three samples (<85%) that were excluded from further 
analysis.
Gene‑based associations
Results from the gene-based tests for association between 
AF candidate genes and AF phenotypes are summarized 
in Table 3. KCNN3 associated with LAD and AF type but 
failed to reach pre-defined significance threshold while 
PITX2 was not consistently associated with any of the phe-
notypes. ZFHX3 was significantly associated with LAD in 
both tools and AF type in VEGAS but not in minSNP.
Therefore, association between ZFHX3 and AF recur-
rence was assessed (Fig.  1). ZFHX3 associated with AF 
recurrence in both data sets and subsequently in the 
entire cohort (P =  0.001 in VEGAS and P =  0.0288 in 
minSNP).
By accessing the publicly available GTEx, a signifi-
cant association between the top ZFHX3 SNP (Fig.  2), 
rs12373097 (OR for LRAF 1.57, 95% CI 1.18–2.08, 
Table 1 Patient characteristics
Total (n = 660) Data set 1 (n = 496) Data set 2 (n = 164) P‑value
Age (years) 60 ± 10 59 ± 10 61 ± 10 ns
Male gender (%) 68 66 75 2.1E−02
Body mass index (kg/m2) 28.9 ± 4.6 28.9 ± 4.5 29.0 ± 4.7 ns
Idiopathic AF (%) 14 13 15 ns
Persistent AF (%) 44 38 61 3.3E−07
LAD (mm) 43 ± 6 42 ± 6 44 ± 6 2.0E−03
LVEF (%) 59 ± 10 60 ± 9 57 ± 10 1.0E−03
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P = 0.002), with a higher expression of ZFHX3 in fibro-
blasts (P  =  8.0E−8) was found. This SNP had a minor 
allele frequency of 20.3 with 32% of patients being het-
erozygous and 4% being homozygous.
Discussion
Main findings
This study is the first to explore the association of AF 
candidate genes and AF remodeling-associated pheno-
types such as left atrial enlargement and AF type as well 
as response to AF catheter ablation using gene-based 
analysis of GWAS data. ZFHX3 was associated with left 
atrial diameter and ablation outcome in two different 
gene-based tests.
Association between genotype, AF phenotypes and AF 
ablation outcomes
Different AF susceptibility alleles have been associ-
ated with non-pulmonary vein triggers and left atrial 
scar [7]. Interestingly, of those SNPs, one ZFHX3 SNP 
(rs7193343) was the only genetic variant that contrib-
uted to increased risk of both phenotypes. Somewhat 
conflicting results have been obtained with left atrial 
parameters. There were no associations between can-
didate SNPs and several left atrial measures in the 
Framingham cohort. However, after excluding preva-
lent AF, a single SNP (rs2200733) in proximity to PITX2 
was associated with left atrial volume following adjust-
ment for body surface area. A second SNP (rs2106261) 
in proximity to the ZFHX3 gene was related to LAD 
[15].
Common genetic variants have also been associated 
with ablation outcome. Of those, the 4q25 variants have 
been shown the strongest association in single-center 
studies and a recent meta-analysis, [8, 10] although 
results have not been consistent [16, 17].
In this study, we focused on gene-based tests and first 
identified an association between genotype and AF phe-
notypes LAD and AF type and then between genotype 
and AF ablation outcome. This was based on the fact 
that left atrial enlargement and AF persistence have con-
sistently been linked with response to AF ablation out-
come [6]. Our study revealed associations of the ZFHX3 
gene with left atrial dilatation and subsequently with 
rhythm outcome. This finding is supported by one previ-
ous study that identified the rs2106216 ZFHX3 genetic 
polymorphism as independent predictor of a good abla-
tion response [15] and strong biological evidence link-
ing ZFHX3 with AF and cardiac remodeling discussed 
below.
ZFHX3 and AF
ZFHX3 encodes a cardiac transcription factor contain-
ing multiple homeodomains and zinc finger motifs and 
common ZFHX3 variants have been shown to increase 
AF risk [3, 18]. Although their cardiac mechanisms 
Table 2 Patient characteristics in patients with and without AF recurrence
One patient was lost to follow-up
AF recurrence (n = 318) No recurrence (n = 341) P‑value
Age (years) 61 ± 10 59 ± 10 7.55E−03
Male gender (%) 70 67 ns
Body mass index (kg/m2) 29.2 ± 4.6 28.7 ± 4.5 ns
Persistent AF (%) 53 35 1.00E−06
LAD (mm) 44 ± 6 42 ± 6 5.42E−05
LVEF (%) 58 ± 10 59 ± 9 ns
Table 3 Gene-based association results
LAD AF type
VEGAS minSNP VEGAS minSNP
KCNN3 0.0153 0.0396 <0.00001 0.0348
PITX2 0.0083 ns ns ns
ZFHX3 0.0001 0.0043 0.0001 ns
Fig. 1 Left atrial enlargement and persistent AF are associated with 
rhythm outcome of AF catheter ablation, but whether or not they are 
associated with AF susceptibility genes is unknown. In this study, we 
found ZFHX3 to be associated with left atrial diameter and, in turn, 
with AF recurrence
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underlying AF remain elusive, several gene effects have 
been demonstrated. For instance, ZFHX3 is related to 
JAK/STAT signaling cascade that mediates the inflam-
matory process thereby contributing to electrical and 
structural remodeling of the atrium with inflammatory 
changes [19]. Interestingly, cross-regulation of gene 
expression of AF candidate genes has been suggested 
as molecular basis for gene–gene interactions [20]. The 
most significant ZFHX3 SNP in our study, rs12373097, 
has been found by eQTL analysis to predict higher 
expression of ZFHX3. ZFHX3 positively regulates 
expression of PITX2 and both ZFHX3 and PITX2 posi-
tively regulate expression of NPPA. Atrial natriuretic 
peptide, the NPPA product, in turn, plays a key role in 
cardiac electrophysiology through APD shortening and 
calcium influx reduction, modulating the autonomic 
nervous system and regulating the function of cardiac 
ion channels [21]. In addition, both ZFHX3 and PITX2 
impact on other downstream genes such as TBX5, 
NKX2.5, KCNQ1 and SCN1B that play critical roles in 
cardiac electrophysiology and AF [20]. Of those, TBX5 
modulation has very recently been found to profoundly 
alter cardiac channel gene expression and to cause pri-
mary, spontaneous AF in mice [22].
Taken together, those and our findings implicate 
ZFHX3 in several AF-remodeling associated processes 
that may underlie left atrial dilatation and AF progression 
and subsequently response to AF catheter ablation.
Limitations
Our study is based on small sample size. However, it 
was based on the three strongest candidate genes that 
were selected for gene-based analysis of GWAS data a 
priori. In other words, although we used GWAS data, 
we applied a hypothesis-driven approach. Furthermore, 
we addressed this by using well-defined intermediate AF 
phenotypes that are known interrelated markers of AF 
ablation outcome. We only selected the gene that showed 
associations with intermediate AF phenotypes for fur-
ther analysis of its association with ablation outcome. 
Finally, we required the genotype–phenotype correlation 
to be present in two different gene-based analysis tools 
accounting for different genetic architectures (multiple 
independent signals versus single signal in a gene, size of 
gene, patterns of LD).
Although we have used two data sets reflecting changes 
in patient characteristics and ablation strategies for abla-
tion outcome, they came from the same institution with 
rs12373097 ( CEU )


































Fig. 2 Regional association plot for all significant ZFHX3 SNPs and response to AF ablation. The plot was created using GWAS association data that 
served as the input for gene-based testing. The x-axis represents the distribution of SNPs across ZFHX3 while the y-axis represents the −log10 of 
the P-value of each SNP in the gene. The colors indicate the r2 between the SNP with the lowest P-value and all the other SNPs. The light blue trace 
indicates recombination hotspots
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all inherent limitations for genetic studies but advan-
tage of coherent patient selection, operators and follow-
up. Despite those differences in clinical characteristics 
ablation outcome was identical. Nevertheless, ablation 
approaches in persistent AF are evolving and linear lesion 
sets have lessened in popularity due to no incremental 
benefit and even pro-arrhythmia. This may impact on 
type of arrhythmia recurrence and should be considered 
when assessing recurrence rates and comparing this to 
other studies.
This study does not contribute to the elaboration of 
molecular mechanisms which was beyond the scope of 
this study and did not address the question whether or 
not genotype impacts on proarrhythmic ablation effects 
or AF progression.
Finally, ablation outcome was assessed with serial clini-
cal and prolonged Holter ECG monitoring which is in 
line with current recommendations but can nevertheless 
miss common asymptomatic AF episodes [23].
Conclusions
These findings suggest a contribution of ZFHX3 to AF 
remodeling and response to AF catheter ablation. Future 
and larger studies are necessary to replicate and apply 
these findings with a clinical emphasis on designing AF 
pathophysiology-based multi-locus risk scores.
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